<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924265</article-id><article-id pub-id-type="pmc">6954570</article-id><article-id pub-id-type="publisher-id">2090</article-id><article-id pub-id-type="doi">10.1186/s13075-019-2090-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Identifying clinical subgroups in IgG4-related disease patients using cluster analysis and IgG4-RD composite score</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Jieqiong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Peng</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuelun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Panpan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Linyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Huadan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Xiaofeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1728-2342</contrib-id><name><surname>Fei</surname><given-names>Yunyun</given-names></name><address><email>feiyunyun2013@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Wen</given-names></name><address><email>Zhangwen91@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution>Department of Rheumatology, </institution><institution>Peking Union Medical College Hospital, Clinical Immunology Center, </institution></institution-wrap>Beijing, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution>Central Research Laboratory, </institution><institution>Peking Union Medical College Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9889 6335</institution-id><institution-id institution-id-type="GRID">grid.413106.1</institution-id><institution>Department of Radiology, </institution><institution>Peking Union Medical College Hospital, </institution></institution-wrap>Beijing, China </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>22</volume><elocation-id>7</elocation-id><history><date date-type="received"><day>17</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To explore the clinical patterns of patients with IgG4-related disease (IgG4-RD) based on laboratory tests and the number of organs involved.</p></sec><sec><title>Methods</title><p id="Par2">Twenty-two baseline variables were obtained from 154 patients with IgG4-RD. Based on principal component analysis (PCA), patients with IgG4-RD were classified into different subgroups using cluster analysis. Additionally, IgG4-RD composite score (IgG4-RD CS) as a comprehensive score was calculated for each patient by principal component evaluation. Multiple linear regression was used to establish the &#x0201c;IgG4-RD CS&#x0201d; prediction model for the comprehensive assessment of IgG4-RD. To evaluate the value of the IgG4-RD CS in the assessment of disease severity, patients in different IgG4-RD CS groups and in different IgG4-RD responder index (RI) groups were compared.</p></sec><sec><title>Results</title><p id="Par3">PCA indicated that the 22 baseline variables of IgG4-RD patients mainly consisted of inflammation, high serum IgG4, multi-organ involvement, and allergy-related phenotypes. Cluster analysis classified patients into three groups: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organs-dominant group. Moreover, there were significant differences in serum and clinical characteristics among subgroups based on the CS and RI scores. IgG4-RD CS had a similar ability to assess disease severity as RI. The &#x0201c;IgG4-RD CS&#x0201d; prediction model was established using four independent variables including lymphocyte count, eosinophil count, IgG levels, and the total number of involved organs.</p></sec><sec><title>Conclusion</title><p id="Par4">Our study indicated that newly diagnosed IgG4-RD patients could be divided into three subgroups. We also showed that the IgG4-RD CS had the potential to be complementary to the RI score, which can help assess disease severity.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>IgG4-related disease</kwd><kwd>Laboratory test</kwd><kwd>Organs involved</kwd><kwd>Cluster analysis</kwd><kwd>IgG4-RD CS</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par26">IgG4-related disease (IgG4-RD) is a multi-organ immune-mediated condition characterized by tumefactive lesions, a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform fibrosis, and, often but not always, elevated serum IgG4 concentrations [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. The comprehensive diagnostic criteria for IgG4-RD were published in 2011 by the Umehara and Okazaki teams [<xref ref-type="bibr" rid="CR4">4</xref>]. The IgG4-RD responder index (RI) is a disease activity tool modeled by Stone et al. [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], wherein the sum of organ sites&#x02019; score (each organ/site graded on a 0&#x02013;4 scale) plus the serum IgG4 concentration score (0&#x02013;4) yields the total RI score. In 2015, an international consensus guidance statement on the management and the treatment of IgG4-RD was published [<xref ref-type="bibr" rid="CR7">7</xref>]. Glucocorticoids (GCs) are the first-line agents for remission induction; some patients require the combination of GCs and steroid-sparing immunosuppressive agents (IMs) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. B cell depletion with rituximab (RTX) is also effective at inducing remission in IgG4-RD [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par27">An increasing number of studies on the outcomes and prediction of disease relapse in IgG4-RD showed that high baseline serum IgG4, IgE, and eosinophilia could predict IgG4-RD relapse independently [<xref ref-type="bibr" rid="CR15">15</xref>]; eosinophilia, higher baseline RI, having five or more organs involved, and dacryoadenitis were risk factors for remission induction failure with GC monotherapy [<xref ref-type="bibr" rid="CR16">16</xref>]; and hypocomplementemia was more frequent in IgG4-related kidney disease (IgG4-RKD), which may participate in the disease development [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. However, the disease subclass, outcomes, and predictors of disease relapse in IgG4-RD still require further exploration.</p><p id="Par28">To our knowledge, no classification of IgG4-RD based on diversified routine blood tests has been proposed. In this study, we aimed to explore the baseline clinical patterns of IgG4-RD based on 19 different types of blood tests and the number of organs involved. We also tried to establish a prediction model for a comprehensive score (IgG4-RD composite score, IgG4-RD CS), which was expected to assess disease severity and partly predict outcomes in IgG4-RD patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par29">This study was approved by the Ethics Committee of Peking Union Medical College Hospital (PUMCH). All the patients provided written and informed consent. The prospective cohort of patients with IgG4-RD in the PUMCH [<xref ref-type="bibr" rid="CR19">19</xref>] was registered on <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT01670695). All the patients fulfilled the 2011 comprehensive diagnostic criteria for definite, probable, or possible IgG4-RD [<xref ref-type="bibr" rid="CR4">4</xref>]. Patients were recruited from 2014 to 2018. The criteria for IgG4-RD patient inclusion in this study were as follows: (1) newly diagnosed patients without treatment and (2) no missing data in 19 different types of blood tests. Data pertaining to demographics, treatments, and laboratory findings at baseline were derived from the medical records.</p></sec><sec id="Sec4"><title>Baseline clinical evaluation and laboratory assessments</title><p id="Par30">Age at onset refers to the age at which the patient first noticed the symptoms attributed to IgG4-RD or to the timepoint at which the disease was first recognized (whichever was earlier) [<xref ref-type="bibr" rid="CR3">3</xref>]. Disease duration refers to the period of time from first symptoms attributed to IgG4-RD to initial diagnosis. Allergic disease history was recorded and confirmed by enquiring each patient, previous allergen detection, and diagnostic reports. The number of organs involved was determined by a review of the patient&#x02019;s history, physical examination, blood tests, imaging, and tissue biopsies. The organs involved were divided into superficial organs (i.e., salivary glands, lacrimal glands, orbit, sinus, and skin) and internal organs (i.e., all of the other organs) [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Lymph nodes were not taken into account when assessing the involvement of the superficial/internal organs [<xref ref-type="bibr" rid="CR20">20</xref>]. Disease activity was assessed using the 2012 IgG4-RD RI [<xref ref-type="bibr" rid="CR5">5</xref>], and the involved organs were evaluated individually. Patients were defined into different RI score grades by separating the RI range of 154 patients into trisection by average.</p><p id="Par31">All obtainable baseline data was recorded before initial treatment. Laboratory tests consisted of complete blood count, urinalysis, liver, and renal function tests, erythrocyte sedimentation rate (ESR), hyper-sensitivity C-reactive protein (hsCRP), complement 3 (C3), C4, serum immunoglobulin (Ig) levels, and total IgE and IgG subclasses. To facilitate application, 19 variables from the laboratory tests involved in this study were the most common routine tests in IgG4-RD clinical practice, including white blood count, lymphocyte count, lymphocyte percentage, eosinophil count, eosinophil percentage, platelet count (Plt), hemoglobin (Hb), ESR, hsCRP, C3, C4, IgG, IgA, IgM, IgE, IgG1, IgG2, IgG3, and IgG4.</p></sec><sec id="Sec5"><title>Definition of disease response</title><p id="Par32">Disease response after initial treatment was assessed after 3&#x02009;months. According to the IgG4-RD RI, disease response was defined as an improvement of the IgG4-RD RI &#x02265;&#x02009;2 compared to the baseline [<xref ref-type="bibr" rid="CR14">14</xref>], and compared to IgG4-RD RI&#x02009;&#x0003c;&#x02009;3 as complete response (CR), IgG4-RD RI remained &#x02265;&#x02009;3 as partial response (PR). No change (NC) was defined as an absence of marked changes in mass sizes, organomegaly and/or symptoms and change of IgG4-RD RI &#x0003c;&#x02009;2 points [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec6"><title>Goals of remission induction</title><p id="Par33">The initial 6-month period was defined as the remission induction stage, and the therapeutic goals of this stage were defined as fulfilling each of the following: (1) &#x02265;&#x02009;50% decline in the IgG4-RD RI, (2) GC tapered to maintenance dose (prednisone &#x02264;&#x02009;10&#x02009;mg/day), and (3) no relapse during GC tapering (within 6&#x02009;months) [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec7"><title>Definition of relapse</title><p id="Par34">Relapse was defined by a review of the new progress or recurrence of symptoms and signs and the new development or return of abnormal findings on physical examination, laboratory tests that reflected IgG4-RD activity within specific organs, or imaging studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The date of relapse was either the date of symptom onset or new or worse physical examination, laboratory, or radiology findings. An isolated increase in the serum IgG4 concentration did not constitute a disease relapse [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par35">All statistical tests were performed using IBM SPSS (version 24). The continuous normally distributed data is presented as mean&#x02009;&#x000b1;&#x02009;standard deviation, non-normally distributed data is presented as median (first quartile, third quartile), and categorical data is presented as a percentage (%). Comparisons of continuous data such as levels of IgG4 among 3 groups were tested using the one-way ANOVA or the Kruskal-Wallis test. Multiple comparisons were performed using the Student-Newman-Keuls test. Categorical variables were assessed using the chi-square or Fisher&#x02019;s exact tests. We also used the chi-square tests to compare the proportion of patients with disease relapse among the different subgroups. We calculated the correlation coefficients among the blood test results such as correlations between IgE and eosinophil count using the Pearson correlation coefficient (normally distributed) or the Spearman correlation coefficient (nonparametric data). A two-sided <italic>P</italic> value &#x0003c;&#x02009;0.05 was considered significant for all statistical testing.</p><p id="Par36">For easy exploration and visualization of 22 baseline variables, which contained 19 variables from laboratory tests and the number of total, internal, and superficial organs involved, and for estimation of the correlation between variables, we used PCA to statistically aggregate these variables, reducing the number of observed variables into a smaller number of principal components (PCs) and reducing the dimensionality of baseline phenotyping data. According to eigenvalues and cumulative contribution rate, we selected the appropriate number of PCs (PC1, PC2, &#x02026;, PCi) with high eigenvalues (<italic>&#x003bb;</italic>&#x02009;&#x0003e;&#x02009;1). According to Component Matrix and eigenvalue, PC scores (the values for extracted PCs) were also calculated in each patient as new variables (F1, F2, &#x02026;, Fi) for further cluster analysis. Cluster analysis was performed using a hierarchical and agglomerative clustering algorithm with the Ward method [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], using the aforementioned new variables of each IgG4-RD patient. We determined the number of clusters based on the tree diagram.</p><p id="Par37">Calculation of IgG4-RD CS involved two steps. First, PCA was applied to 22 variables to derive PCs representing large fractions of variance. Second, IgG4-RD CS was computed by summing individual PC scores (F1, F2, &#x02026;, Fi) with the contribution rate(C&#x02009;=&#x02009;<italic>&#x003bb;</italic>/<italic>p</italic>, <italic>p</italic>&#x02009;=&#x02009;22) as weight coefficient for each patient (IgG4-RD SC&#x02009;=&#x02009;C1F1&#x02009;+&#x02009;C2F2&#x02009;+&#x02009;...&#x02009;+&#x02009;CiFi), which enabled us to group patients according to their IgG4-RD CS grades by separating the IgG4-RD CS range into trisection averages. Finally, a mathematical model for the &#x0201c;IgG4-RD CS&#x0201d; was established using multivariate linear regression.</p><p id="Par38">The flow scheme of statistical analysis, patients grouping, and comparisons among subgroups is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.
<fig id="Fig1"><label>Fig. 1</label><caption><p>The flow scheme of statistical analysis, patients&#x02019; grouping, and comparisons among subgroups. PCA, principal components analysis; PCs, principal components; RI, IgG4-RD responder index (2012); IgG4-RD CS, IgG4-RD composite score</p></caption><graphic xlink:href="13075_2019_2090_Fig1_HTML" id="MO1"/></fig></p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Demographic and clinical characteristics</title><p id="Par39">One hundred and fifty-four newly diagnosed patients were included in this study. There were 99 male and 55 female patients (male to female 1.8:1). The average age at onset was 53.35&#x02009;years (&#x000b1;&#x02009;13.2, range 9&#x02013;83). The median duration of disease was 11.5&#x02009;months (range 10&#x02009;days to 20&#x02009;years). There were 68 (44.16%) patients with a history of allergies (male to female 1.5:1). There were 87 (56.49%), 3 (1.95%), and 64 (41.56%) cases, which were diagnosed as definite, probable, and possible IgG4-RD, respectively.</p><p id="Par40">Of the 154 patients, the median number of the total organs involved was 3 (range 1&#x02013;8). About 30% (46/154) had only superficial organ involvement, and 31% (48/154) had only internal organ involvement. The median IgG4-RD RI was 11.5 (range 3&#x02013;28). The detailed demographic and clinical characteristics are shown in Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>.</p></sec><sec id="Sec11"><title>Correlations of serological variables</title><p id="Par41">With regard to the correlations between serological variables, we mainly focused on IgG4, IgG, IgE, ESR, and CRP. Serum IgG4 concentration showed positive correlations with serum IgG concentration (<italic>r</italic>&#x02009;=&#x02009;0.604, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), IgE (<italic>r</italic>&#x02009;=&#x02009;0.359, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and IgG3 (<italic>r</italic>&#x02009;=&#x02009;0.272, <italic>P</italic>&#x02009;=&#x02009;0.001) and negative correlations with IgA (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.442, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), IgM (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.265, <italic>P</italic>&#x02009;=&#x02009;0.001), C3 (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.338, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and C4 (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.41, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par42">Serum IgG concentration correlated positively with IgE (<italic>r</italic>&#x02009;=&#x02009;0.243, <italic>P</italic>&#x02009;=&#x02009;0.002), ESR (<italic>r</italic>&#x000a0;=&#x02009;0.587, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), CRP (<italic>r</italic>&#x000a0;=&#x02009;0.225, <italic>P</italic>&#x02009;=&#x02009;0.005), as well as Plt (r&#x02009;=&#x02009;0.204, <italic>P</italic>&#x02009;=&#x02009;0.011) and negatively with C3 (r&#x02009;=&#x02009;&#x02212;&#x02009;0.193, <italic>P</italic>&#x02009;=&#x02009;0.016), C4 (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.315, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and Hb (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.36, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par43">As for serum IgE levels, positive correlations were found between IgE and eosinophil count (<italic>r</italic>&#x02009;=&#x02009;0.257, <italic>P</italic>&#x02009;=&#x02009;0.001), as well as eosinophil proportion (<italic>r</italic>&#x02009;=&#x02009;0.25, <italic>P</italic>&#x02009;=&#x02009;0.002).</p><p id="Par44">We also investigated the correlations between RI and serological variables. RI scores showed positive correlations with serum IgG4 (<italic>r</italic>&#x02009;=&#x02009;0.589, <italic>P</italic>&#x02009;=&#x02009;&#x0003c;&#x02009;0.001), IgG (<italic>r</italic>&#x02009;=&#x02009;0.333, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), IgE (<italic>r</italic>&#x02009;=&#x02009;0.267, <italic>P</italic>&#x02009;=&#x02009;0.001), IgG3 (<italic>r</italic>&#x02009;=&#x02009;0.231, <italic>P</italic>&#x02009;=&#x02009;0.004), and eosinophil count (<italic>r</italic>&#x02009;=&#x02009;0.223, <italic>P</italic>&#x02009;=&#x02009;0.005) as well as eosinophil proportion (<italic>r</italic>&#x02009;=&#x02009;0.229, <italic>P</italic>&#x02009;=&#x02009;0.004) and negative correlations with IgA (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.366, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), C3 (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.389, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and C4 (<italic>r</italic>&#x02009;=&#x02009;&#x02212;&#x02009;0.488, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec id="Sec12"><title>Clinical phenotypes based on PCA</title><p id="Par45">Seven PCs (eigenvalue, <italic>&#x003bb;</italic>1&#x02013;7&#x02009;=&#x02009;4.317, 3.794, 2.33, 1.798, 1.468, 1.23, 1.198) were extracted from 22 baseline variables by PCA, and the cumulative score was up to 73.34% (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a and Additional&#x000a0;file&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>). The correlation coefficient shown in the Component Matrix reflected the ability of each PC to represent the original variable, and baseline variables were statistically aggregated to the 7 PCs (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). For easier exploration and visualization of these baseline variables, we also created a 3-dimensional loading plot as well as 2-dimensional images from different plane angles (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x02013;e). The PCA results showed that PC1 was associated with the inflammatory phenotype. The positive side of PC1 contained ESR, CRP, IgG1, IgG3, IgG, and Plt, while the negative side contained Hb. PC2 seemed to be mainly associated with the disease severity of IgG4-RD, for the positive side contained IgG4 and number of the total organs involved. PC3 predominantly showed allergy-related variables, as the positive side contained IgE, eosinophil count, and eosinophil proportion. The correlation coefficient was also shown in the Component Matrix of the first 3 PCs (Additional&#x000a0;file&#x000a0;<xref rid="MOESM3" ref-type="media">3</xref>). Additionally, we further explored the distances between variables to help clarify the correlations among the baseline variables (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x02013;e). Both C3 and C4 were statistically opposed to and showed negative correlations with the number of total organs involved as well as that of superficial organs involved (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). IgA and CRP were statistically close and showed positive correlation (<italic>r</italic>&#x02009;=&#x02009;0.214, <italic>P</italic>&#x02009;=&#x02009;0.008). The results of the PCA indicated that the baseline phenotypes of IgG4-RD basically consisted of the inflammation-related axis, disease severity-related axis, and allergy-related axis abnormalities.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Results of PCA based on 22 baseline variables. <bold>a</bold> Scree plot. Every hollow spot represents one principal component. Vertical axis shows eigenvalue of each spot. <bold>b</bold>&#x02013;<bold>e</bold> Loading plot. Each baseline variable was visualized in 3 dimensions (<bold>b</bold>). Planes consisting of axis PC1 and PC2, PC2 and PC3, and PC3 and PC1 are colored green, light purple, and blue. LY.ab, absolute lymphocyte count; Ly.per, lymphocyte percentage; Eos.ab, absolute eosinophil count; Eos.per, Eosinophil percentage; <ext-link ext-link-type="uri" xlink:href="http://total.org">total.org</ext-link>, the number of total organs involved; <ext-link ext-link-type="uri" xlink:href="http://superficial.org">superficial.org</ext-link>, the number of superficial organs involved; <ext-link ext-link-type="uri" xlink:href="http://internal.org">internal.org</ext-link>, the number of internal organs involved</p></caption><graphic xlink:href="13075_2019_2090_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Correlation coefficient of each phenotype after extracting 7 PCs</p></caption><graphic position="anchor" xlink:href="13075_2019_2090_Tab1_HTML" id="MO3"/><table-wrap-foot><p><sup>a</sup>Seven components were extracted. Red represents the positive value, blue represents the negative value. The color depth of each cell is proportional to the absolute value of correlation coefficient</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Clinical subgroups by cluster analysis</title><p id="Par46">Based on the 7 PCs, cluster analysis revealed that the 154 newly diagnosed patients with IgG4-RD could be classified into 3 subgroups (termed clusters 1, 2, 3; <italic>n</italic>&#x02009;=&#x02009;20, <italic>n</italic>&#x02009;=&#x02009;68, <italic>n</italic>&#x02009;=&#x02009;66, respectively) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). We explored the baseline features of the 3 clusters (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The major statistical differences among clusters also are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. Cluster 1 had the highest serum levels of IgG, IgG1, IgG3, ESR, and CRP, but the lowest level of C4 (termed the inflammation and immunoglobulin-dominant group). Cluster 2 had the highest proportion of internal organ to total organ involvement (termed the internal organs-dominant group). In contrast, cluster 3 had the highest number of superficial organs involved, while the lowest proportion of internal organ to total organ involved, and the lowest levels of ESR, CRP, and IgG2 (termed inflammation and immunoglobulin-low with superficial organ-dominant group).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Results of cluster analysis and differences among clusters. <bold>a</bold> Three clusters of patients identified by cluster analysis. Hierarchical statistical clustering of IgG4-RD patients. <bold>b</bold>&#x02013;<bold>j</bold> Comparisons of baseline characteristics among three clusters of IgG4-RD patients. Inter.ratio, proportion of internal organs to total organs involved. *<italic>P</italic> value &#x0003c;&#x02009;0.05; **<italic>P</italic> value &#x0003c;&#x02009;0.01; ***<italic>P</italic> value &#x0003c;&#x02009;0.001</p></caption><graphic xlink:href="13075_2019_2090_Fig3_HTML" id="MO4"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline characteristics of patients with IgG4-RD grouped by cluster analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cluster 1<break/><italic>n</italic>&#x02009;=&#x02009;20</th><th>Cluster 2<break/><italic>n</italic>&#x02009;=&#x02009;68</th><th>Cluster 3<break/><italic>n</italic>&#x02009;=&#x02009;66</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Sex (male; female)</td><td>2.33:1</td><td>3.533:1</td><td>0.94:1</td><td>0.002</td></tr><tr><td>Age (years)</td><td>54.3&#x02009;&#x000b1;&#x02009;12.24</td><td>55.07&#x02009;&#x000b1;&#x02009;14.66</td><td>51.29&#x02009;&#x000b1;&#x02009;11.63</td><td>0.237</td></tr><tr><td>Disease duration (months)</td><td>12 (7, 24)</td><td>6 (2, 22.5)</td><td>12 (6, 36)</td><td>0.667</td></tr><tr><td>IgG4-RD RI</td><td>12.5 (10, 18.25)</td><td>12 (7, 15)</td><td>11 (7, 15)</td><td>0.203</td></tr><tr><td>Allergy history, <italic>n</italic> (%)</td><td>5 (25%)</td><td>33 (48.53%)</td><td>30 (45.45%)</td><td>0.17</td></tr><tr><td>Number of total organs involved</td><td>3 (2, 4.75)</td><td>3 (2, 4)</td><td>3 (2, 4)</td><td>0.3</td></tr><tr><td>Number of internal organs</td><td>2 (1, 2)</td><td>2 (1, 2.75)</td><td>0 (0, 1)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Number of superficial organs</td><td>1 (0, 2)</td><td>0 (0, 2)</td><td>2 (1, 3)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>Internal organs ratio</td><td>0.41 (0.33, 0.67)</td><td>0.67 (0.5, 1)</td><td>0 (0, 0.25)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="5">Laboratory test at baseline</td></tr><tr><td>&#x02003;WBC (&#x000d7;10<sup>9</sup>/L)</td><td>7.93 (5.72, 8.33)</td><td>7.03 (5.86, 8.36)</td><td>6.09 (5.37, 7.03)</td><td>0.002</td></tr><tr><td>&#x02003;Eosinophils (&#x000d7;10<sup>9</sup>/L)</td><td>0.35 (0.11, 0.69)</td><td>0.23 (0.09, 0.45)</td><td>0.23 (0.14, 0.37)</td><td>0.615</td></tr><tr><td>&#x02003;Eosinophils (%)</td><td>3.45 (1.43, 7.45)</td><td>3.15 (1.25, 5.95)</td><td>3.4 (1.98, 6.53)</td><td>0.836</td></tr><tr><td>&#x02003;Lymphocyte (&#x000d7;10<sup>9</sup>/L)</td><td>2.05 (1.78, 2.51)</td><td>2.09 (1.55, 2.58)</td><td>1.70 (1.54, 2.27)</td><td>0.091</td></tr><tr><td>&#x02003;Lymphocyte (%)</td><td>29.24 (23.30, 33.79)</td><td>30.29 (22.16, 36.20)</td><td>30.73 (25.34, 36.82)</td><td>0.667</td></tr><tr><td>&#x02003;Hemoglobin(g/L)</td><td>115 (98, 125)</td><td>138 (125.25, 149)</td><td>140.5 (131, 153.75)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;Plt (&#x000d7;10<sup>9</sup>/L)</td><td>303 (227.5, 386.75)</td><td>242 (180.5, 277.75)</td><td>232 (206, 282)</td><td>0.001</td></tr><tr><td>&#x02003;ESR (mm/h)</td><td>97 (80.5, 112.75)</td><td>22 (7.25, 41.5)</td><td>11 (5, 25)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;CRP (mg/L)</td><td>44.54 (5.01, 78.37)</td><td>2.64 (0.74, 9.61)</td><td>1.19 (0.36, 3.73)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;IgG (g/L)</td><td>39.77 (24.48, 47.84)</td><td>18.40 (14.74, 23.43)</td><td>17.53 (13.87, 21.40)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;IgA (g/L)</td><td>2.74 (0.85, 5.02)</td><td>2.23 (1.59, 2.84)</td><td>1.79 (1.33, 2.34)</td><td>0.087</td></tr><tr><td>&#x02003;IgM (g/L)</td><td>0.88 (0.47, 1.57)</td><td>0.87 (0.58, 1.17)</td><td>0.90 (0.58, 1.41)</td><td>0.48</td></tr><tr><td>&#x02003;IgG1 (mg/L)</td><td>15,100 (12,125, 29,900)</td><td>9175 (7242.5, 11,000)</td><td>8750 (7290, 10,200)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;IgG2 (mg/L)</td><td>7455 (5127.5, 9942.5)</td><td>6560 (5060, 8575)</td><td>5535 (4415, 6962.5)</td><td>0.021</td></tr><tr><td>&#x02003;IgG3 (mg/L)</td><td>1035 (590.25, 2240)</td><td>289.5 (195, 662)</td><td>422.5 (263, 711.5)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x02003;IgG4 (mg/L)</td><td>12,550 (2860, 52,975)</td><td>8535 (3085, 14,250)</td><td>7895 (4235, 14,725)</td><td>0.261</td></tr><tr><td>&#x02003;IgE (kU/L)</td><td>546.5 (163.25, 1340.5)</td><td>275 (151.75, 855.75)</td><td>369 (99.2, 632.25)</td><td>0.183</td></tr><tr><td>&#x02003;C3 (g/L)</td><td>0.88 (0.39, 1.51)</td><td>1.03 (0.86, 1.19)</td><td>0.95 (0.75, 1.04)</td><td>0.077</td></tr><tr><td>&#x02003;C4 (g/L)</td><td>0.14 (0.03, 0.20)</td><td>0.20 (0.12, 0.27)</td><td>0.17 (0.13, 0.21)</td><td>0.03</td></tr><tr><td>&#x02003;IgG4-RD CS</td><td>1.13 (0.37, 1.31)</td><td>&#x02212;&#x02009;0.06 (&#x02212;&#x02009;0.43, 0.26)</td><td>&#x02212;&#x02009;0.22 (&#x02212;&#x02009;0.48, &#x02212;&#x02009;0.08)</td><td>&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p>The continuous normally distributed data are presented as mean&#x02009;&#x000b1;&#x02009;standard deviation; non-normally distributed data are presented as median (first quartile, third quartile)</p></table-wrap-foot></table-wrap></p><p id="Par47">To further clarify the situation of complement in clusters, we divided the levels of C3 and C4 into 3 grades respectively: low, normal, and high-levels (Additional file&#x000a0;<xref rid="MOESM4" ref-type="media">4</xref>a). We found significant statistical differences in both C3 and C4 among clusters 1&#x02013;3 using chi-square tests (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>P</italic>&#x02009;=&#x02009;0.043, respectively). Cluster 1 had the highest percentage of patients with low-level complement (45%), while most patients in cluster 2 and cluster 3 had normal-level complement (73.53%, 75.75%).</p><p id="Par48">There was no statistical difference in the RI among the 3 clusters (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). These findings indicated that the baseline features were different even among patients with similar RI. Indeed, it was difficult to distinguish subgroups adequately according to RI only.</p><p id="Par49">In addition, we repeated cluster analysis in different genders. The results showed that IgG4-RD patients also could be classified into three clusters no matter in male or female patients: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organs-dominant group; cluster 3, superficial organs-dominant group (Additional&#x000a0;files&#x000a0;<xref rid="MOESM5" ref-type="media">5</xref>,&#x000a0;<xref rid="MOESM6" ref-type="media">6</xref>, and&#x000a0;<xref rid="MOESM7" ref-type="media">7</xref>).</p></sec><sec id="Sec14"><title>Group by IgG4-RD CS</title><p id="Par50">Each patient was given a unique IgG4-RD CS by the aforementioned synthetical constructor (IgG4-RD CS=C1F1&#x02009;+&#x02009;C2F2&#x02009;+&#x02009;...&#x02009;+&#x02009;C7F7) as the comprehensive reflection of 22 baseline variables. All 154 patients had a median CS of &#x02212;&#x02009;0.1149 (range &#x02212;&#x02009;1.223 to 1.996).</p><p id="Par51">Next, we defined IgG4-RD CS grades by dividing the range into trisection by average (grade 1, range &#x02212;&#x02009;1.5 to &#x02212;&#x02009;0.3; grade 2, range &#x02212;&#x02009;0.3 to 0.9; grade 3, range 0.9 to 2.1) and divided 154 patients into 3 groups (termed CS1, 2, 3; <italic>n</italic>&#x02009;=&#x02009;51, <italic>n</italic>&#x02009;=&#x02009;90, <italic>n</italic>&#x02009;=&#x02009;13) accordingly. Then, we compared 22 baseline variables among CS1&#x02013;3. As expected, we found statistical differences in RI, the number of internal organs involved, the number of total organs involved, lymphocyte count, eosinophil count, ESR, Hb, IgG, IgG1, IgG3, IgG4, C4, and other variables among CS1&#x02013;3 (Additional&#x000a0;files&#x000a0;<xref rid="MOESM9" ref-type="media">9</xref> and&#x000a0;<xref rid="MOESM10" ref-type="media">10</xref>). These findings indicated that the synthetical constructor was successful and able to represent the baseline features for each patient to a great extent, especially the disease severity.</p><p id="Par52">We also explored the relation of the IgG4-RD CS grades to clusters. Interestingly, there were significant differences in the IgG4-RD CS among the 3 clusters, and cluster 1 had the highest percentage of CS3, while cluster 3 had the highest percentage of CS1 (Additional file&#x000a0;<xref rid="MOESM4" ref-type="media">4</xref>b-c).</p></sec><sec id="Sec15"><title>Treatment and outcomes</title><p id="Par53">Among 154 IgG4-RD patients, treatment regimens mainly included GC monotherapy, GC combined with IMs, and GC-sparing medications or &#x0201c;watchful waiting&#x0201d; (16.9%, 60.8%, 22.3%, respectively). We explored the treatment response, remission, and disease relapse. There were 5 patients with no change to treatment, 51 patients with partial responses, and 64 patients with complete responses. Twelve patients (13.3%) failed to achieve remission among those with GC therapy. There were 31 patients (20.1%) who had experienced relapse or were in recurrent states.</p><p id="Par54">We divided 154 patients into 3 new groups (termed RI 1, 2, 3; <italic>n</italic>&#x02009;=&#x02009;71, <italic>n</italic>&#x02009;=&#x02009;74, <italic>n</italic>&#x02009;=&#x02009;9, respectively) again according to the RI score by dividing the range into trisection by average (range 3&#x02013;28; RI1, range 0&#x02013;10; RI2, range 11&#x02013;20; RI3, range 21&#x02013;30) and explored the differences in the treatment regimens among different subgroups using chi-square tests (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a&#x02013;c). There were significant statistical differences in treatment among clusters 1&#x02013;3, CS1&#x02013;3, and RI 1&#x02013;3 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>P</italic>&#x02009;=&#x02009;0.002, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively), and both CS1 and RI1 had the highest proportion of patients without GC treatment (38.8%, 40.0%, respectively). Interestingly, we also found IgG4-RD CS had superior ability to guide treatment in female patients. In male patients, IgG4-RD CS and IgG4-RD RI shared the similar trends corresponding to clusters; cluster 1 and cluster 2 showed higher disease severity scores (both RI and IgG4-RD CS), which was consistent with higher probability of receiving active treatments (GC or GC+IM) (Additional file&#x000a0;<xref rid="MOESM8" ref-type="media">8 </xref>a, c). In female patients, however, RI was the lowest in cluster 1 but highest in cluster 3, and female patients in cluster 1 received active intervention proportionately with higher IgG4-RD CS but lower RI (Additional file&#x000a0;<xref rid="MOESM8" ref-type="media">8 </xref>b, d).
<fig id="Fig4"><label>Fig. 4</label><caption><p>Comparisons of treatments and disease responses among subgroups. <bold>a</bold>&#x02013;<bold>c</bold> Percent of the treatment regimens among different subgroups. <bold>d</bold>&#x02013;<bold>f</bold> Disease responses were compared among subgroups. CR, complete response; PR, partial response; NC, no change. *<italic>P</italic> value &#x0003c;&#x02009;0.05; **<italic>P</italic> value &#x0003c;&#x02009;0.01</p></caption><graphic xlink:href="13075_2019_2090_Fig4_HTML" id="MO5"/></fig></p><p id="Par55">In total patients, there were significant statistical differences in disease response among CS1&#x02013;3 and RI1&#x02013;3 (<italic>P</italic>&#x02009;=&#x02009;0.019, <italic>P</italic>&#x02009;=&#x02009;0.0058, respectively), and subgroup CS1 had the highest proportion of patients with CR as well as subgroup RI1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d&#x02013;f). However, no difference was found in remission induction or disease relapse (Additional file&#x000a0;<xref rid="MOESM11" ref-type="media">11 </xref>a-b).</p><p id="Par56">Considering that the recurrence rate was time-varying, we explored the dynamic changes of relapse situations among groups. There was no difference in the cumulative relapse rate as observed using Kaplan-Meier curves, but we found the half-relapse time was different among groups (Additional file&#x000a0;<xref rid="MOESM12" ref-type="media">12</xref> a-c). Cluster 2, CS2, and RI2 had the relatively long half-relapse time than cluster 3, CS1, and RI1, respectively. In addition, we also showed the real-time proportion of non-relapse patients in follow-up patients (Additional file&#x000a0;<xref rid="MOESM12" ref-type="media">12</xref>d-i), for the patients in subgroup CS3 was not enough to form a curve; the figure of CS3 has not been shown.</p></sec><sec id="Sec16"><title>Establishment of IgG4-RD CS prediction model for assessment of IgG4-RD</title><p id="Par57">We used stepwise multiple linear regression to establish an IgG4-RD CS prediction model for IgG4-RD. The multiple regression equation was &#x0201c;IgG4-RD CS = 0.038*IgG(g/L) + 0.385*eosinophil count (10<sup>9</sup>/L) + 0.247*lymphocyte count (10<sup>9</sup>/L) + 0.135*total organs involved number &#x02212; 1.852&#x0201d;. The 95% confidence interval (95% CI) of these four independent variables and constants were shown as follows: IgG (0.035, 0.04), eosinophil count (0.329, 0.44), lymphocyte count (0.209, 0.285), total number of organs involved (0.118, 0.151), and constant (&#x02212;&#x02009;1.958, &#x02212;&#x02009;1.746). The model had excellent adjusted <italic>R</italic> square (<italic>R</italic><sup>2</sup>adj, 0.918) and Durbin-Watson value (DW&#x02009;=&#x02009;1.842). The plot of residuals also indicated that the model was a statistical success (Additional&#x000a0;file&#x000a0;<xref rid="MOESM13" ref-type="media">13</xref>).</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par58">In this paper, we identified abnormalities of the baseline phenotype of IgG4-RD and classified IgG4-RD patients into subgroups based on 22 baseline variables using PCA and cluster analysis. We also calculated the &#x0201c;IgG4-RD CS&#x0201d; as a comprehensive score for each patient using principal component evaluation and explored its capability of disease severity assessment.</p><p id="Par59">IgG4-RD is a heterogeneous disease [<xref ref-type="bibr" rid="CR26">26</xref>]. Wallace et al. [<xref ref-type="bibr" rid="CR27">27</xref>] identified four distinctive IgG4-RD phenotypes according to organ involvement using latent class analysis. Regarding the heterogeneity in serology, one of the major characteristics of IgG4-RD is elevation of serum IgG4, and studies have generally attached crucial importance to serum IgG4 concentrations, which is also used to assess disease activity [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. However, serum elevation of IgG4 is the lack of specificity, and normal serum IgG4 concentrations are described even in the setting of active, biopsy-proven disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, a high percentage of eosinophil; high levels of IgG, IgE, ESR, and CRP; and hypocomplementemia have been frequently reported in IgG4-RD and have been related to outcomes [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], but without excellent specificity. Herein, we proposed clinical patterns in IgG4-RD using cluster analysis based on various baseline blood tests.</p><p id="Par60">PCA showed major abnormalities in IgG4-RD (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x02013;e, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Additional file&#x000a0;<xref rid="MOESM3" ref-type="media">3</xref>), which have also been described in earlier studies [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Complement levels showed negative correlations with IgG4, IgG, and RI and were at the opposite sites of organs involved number in the PCA graph (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b&#x02013;e), which is consistent with the conclusion reported in previous studies that hypocomplementemia is related to disease activity [<xref ref-type="bibr" rid="CR33">33</xref>]. We also found that IgA had a negative correlation with IgG4. Though there are few studies on the role of IgA in IgG4-RD, a recent study has reported that patients with relapse had significantly higher levels of serum IgG4 but lower levels of serum IgA compared to patients without relapse [<xref ref-type="bibr" rid="CR30">30</xref>], and the lower level of serum IgA is used to differentiate IgG4-RD from hyper-interleukin (IL-) 6 syndromes such as multicentric Castleman&#x02019;s disease [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par61">In this study, IgG4-RD patients could be stratified statistically into three clusters (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). High levels of inflammation and immunoglobulin were especially noted in cluster 1 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b&#x02013;j). Moreover, about 33% of patients in cluster 1 failed to achieve remission induction during the 6-month period (Additional file&#x000a0;<xref rid="MOESM11" ref-type="media">11</xref>a), which was partly because of a small sample size and heterogeneity of follow-up duration, in addition to the disease characteristics of cluster 1. Cluster 2 had a high percentage of internal organ involvement (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>j). Patients in cluster 2 had the longest half-relapse time of about 48&#x02009;months (Additional file&#x000a0;<xref rid="MOESM12" ref-type="media">12</xref>a), which resulted from receiving more aggressive treatment because of the high percentage of internal organs involved. Conversely, cluster 3 was characterized by lower levels of serum inflammation and immunoglobulin compared with cluster 1, and a higher percentage of superficial organs involved in contrast to cluster 2 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par62">In addition, the sex ratios were different between cluster 2 and cluster 3. We have known that IgG4-RD has a gender predilection [<xref ref-type="bibr" rid="CR1">1</xref>]. Female patients present more frequently with superficial organ involvement, while male patients more frequently have internal organ involvement [<xref ref-type="bibr" rid="CR20">20</xref>]. Similarly, our cluster analysis results indicated that cluster 2 was characterized by internal organ-dominant (male to female, 3.53:1) and cluster 3 was characterized by superficial organ-dominant (male to female, 0.94:1). Although there were many common characteristics in the male and female clusters after reanalysis in different genders (Additional files&#x000a0;<xref rid="MOESM5" ref-type="media">5</xref>,&#x000a0;<xref rid="MOESM6" ref-type="media">6</xref>, and&#x000a0;<xref rid="MOESM7" ref-type="media">7</xref>), we found some subtle but interesting differences. The relationship between the organs involved and inflammation or disease activity in male patients were closer to those in the total number of patients, while in female patients showed several heterogenicities. And IgG4-RD CS had superior ability to guide treatment in female patients (Additional file&#x000a0;<xref rid="MOESM8" ref-type="media">8</xref>). The RI score for an organ site at baseline is 3 [<xref ref-type="bibr" rid="CR5">5</xref>], no matter it is internal organ or superficial organ except for a particular or organ/site which is considered urgent. Thus, female patients characterized by superficial organs-dominant will receive overestimated RI scores compared with male patients.</p><p id="Par63">As for treatment of total patients, patients in cluster 3 had the highest probability to receive &#x0201c;watchful waiting&#x0201d; (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). At the same time, cluster 3 had a shorter half-relapse time of about 24&#x02009;months (Additional file&#x000a0;<xref rid="MOESM12" ref-type="media">12</xref>a), which probably attributes to not only lighter treatment, but also lower disease attentions from patients. Therefore, close clinical follow-up and/or regular imaging checks are highlighted in IgG4-RD &#x0201c;watchful waiting&#x0201d; [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. No difference in RI among clusters 1&#x02013;3 indicates that baseline heterogeneity exists in patients with a similar level of RI.</p><p id="Par64">IgG-RD CS as a comprehensive score has several unique advantages. Firstly, it is more comprehensive. It was calculated from 22 baseline variables representing the disease heterogeneity presumably driven by differences in underlying molecular pathology better than RI. Secondly, IgG4-RD CS identified clinical subgroups perfectly (Additional file&#x000a0;<xref rid="MOESM4" ref-type="media">4</xref> b-c) and was comparable to RI in assessing disease severity, reflecting and corresponding with treatment plans, and predicting drug responses and disease relapse (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Additional files&#x000a0;<xref rid="MOESM9" ref-type="media">9</xref>,&#x000a0;<xref rid="MOESM10" ref-type="media">10</xref>,&#x000a0;<xref rid="MOESM11" ref-type="media">11</xref>, and&#x000a0;<xref rid="MOESM12" ref-type="media">12</xref>), which also confirmed the value of IgG4-RD CS as a practical comprehensive assessment. Thirdly, IgG4-RD CS was potentially a novel disease assessment tool in clinical practice, because it is computable and objective. The application of RI may be difficult if there are serum-negative patients, or the organ site score is subjective and even not very accurate especially without whole body organ screening. IgG4-RD CS enables assessment and clinical predictions to be made quickly, without the requirement for sophisticated analyses. And the independents introduced in IgG4-RD CS prediction model are supported by previous evidences. Such abnormalities of specific lymphocyte subsets are present in the blood of patients with IgG4-RD, including CD4+ cytotoxic T lymphocytes (CTL), follicular helper T (Tfh) cell, CD19+CD24&#x02212;CD38hi plasmablasts/plasma cells, and so on [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>], and the role of Eosinophil in IgG4-RD has been reported in previous studies [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Finally, after we performed cluster analysis in different genders, IgG4-RD CS presented superior ability to guide treatment in female patients.</p><p id="Par65">Our study has several limitations. First, it was exploratory and the &#x0201c;IgG4-RD CS&#x0201d; prediction model was not validated by investigation of other cohorts. Second, we did not find significant differences in remission induction or disease relapse among groups (Additional&#x000a0;file&#x000a0;<xref rid="MOESM11" ref-type="media">11</xref>). It may be caused by individual treatment, as data collected from a real world study are different in terms of the follow-up time and other confounding factors. Finally, some variables with a potential role in the pathogenesis of IgG4-RD were not investigated, such as ANA, RF, and neutrophils [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par66">In conclusion, according to our definition, the baseline phenotypes of IgG4-RD consisted of inflammation-related axis, disease severity-related axis, and allergy-related axis abnormalities and 154 newly diagnosed patients with IgG4-RD could be classified into three clusters: cluster 1, inflammation and immunoglobulin-dominant group; cluster 2, internal organ-dominant group; and cluster 3, inflammation and immunoglobulin-low with superficial organ-dominant group. In addition, there were significant differences in serum and clinical characteristics among subgroups based on IgG4-RD CS, which indicated that the IgG4-RD CS had the ability to assess disease severity. Subsequently, the &#x0201c;IgG4-RD CS&#x0201d; prediction model introduced 4 independent variables and needs further validation. Accumulation of further evidence along these lines will not only contribute to the identification of clinical phenotypes, but also help in the elucidation of the pathogenesis of IgG4-RD.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec19"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13075_2019_2090_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold> Baseline characteristics of patients with IgG4-RD (<italic>n</italic>&#x02009;=&#x02009;154).</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13075_2019_2090_MOESM2_ESM.docx"><caption><p><bold>Additional file 2.</bold> Eigenvalue and variance contribution.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13075_2019_2090_MOESM3_ESM.docx"><caption><p><bold>Additional file 3.</bold> Correlation coefficient of each phenotype after extracting 3 PCs.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13075_2019_2090_MOESM4_ESM.docx"><caption><p><bold>Additional file 4.</bold> Other differences among Clusters. a, Distribution of the grades of complement in clusters. Normal values of C3 and C4 were 0.73-1.46 and 0.1-0.4(g/L), respectively. b, Distribution of the grades of IgG4-RD CS in clusters. (CS1, range-1.5 to -0.3; CS2, range -0.3 to 0.9; CS3, range 0.9 to 2.1). c, IgG4-RD CS was compared between clusters. *, <italic>P</italic> value &#x0003c;0.05; ***, P value &#x0003c;0.001.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13075_2019_2090_MOESM5_ESM.docx"><caption><p><bold>Additional file 5.</bold> Three clusters of patients identified by cluster analysis in male and female IgG4-RD patients. cluster1, inflammation and immunoglobulin-dominant group; cluster2, internal organs-dominant group; cluster3, superficial organs-dominant group.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="13075_2019_2090_MOESM6_ESM.docx"><caption><p><bold>Additional file 6.</bold> Comparisons of baseline characteristics among three clusters of male IgG4-RD patients. *, P value &#x0003c;0.05; **, P value &#x0003c;0.01; ***, P value &#x0003c;0.001.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="13075_2019_2090_MOESM7_ESM.docx"><caption><p><bold>Additional file 7.</bold> Comparisons of baseline characteristics among three clusters of female IgG4-RD patients. Inter.ratio, proportion of internal organs to total organs involved. *, P value &#x0003c;0.05; **, P value &#x0003c;0.01; ***, P value &#x0003c;0.001.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="13075_2019_2090_MOESM8_ESM.docx"><caption><p><bold>Additional file 8.</bold> Disease severity scores (mean&#x02009;&#x000b1;&#x02009;SD) and percentages of different treatments in male and female IgG-RD patients. a, IgG4-RD CS and IgG4-RD RI in male patients; b, IgG4-RD CS and IgG4-RD RI (mean&#x000b1;SD) in female patients; c, Percentages of different treatments in male patients; d, Percentages of different treatments in female patients.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="13075_2019_2090_MOESM9_ESM.docx"><caption><p><bold>Additional file 9.</bold> Comparisons of baseline characteristics among CS1-3 grouped by IgG4-RD composite score. *, P value &#x0003c;0.05; **, P value &#x0003c;0.01; ***, P value &#x0003c;0.001.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="13075_2019_2090_MOESM10_ESM.docx"><caption><p><bold>Additional file 10.</bold> Baseline characteristics of patients with IgG4-RD grouped by IgG4-RD CS.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="13075_2019_2090_MOESM11_ESM.docx"><caption><p><bold>Additional file 11.</bold> Comparisons of remission induction and disease relapse among subgroups. a-b, the remission induction and disease relapse among different subgroups were shown in pie charts.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="13075_2019_2090_MOESM12_ESM.docx"><caption><p><bold>Additional file 12.</bold> Comparisons of relapse rate among subgroups. a-c, No difference in cumulative relapse rate by Kaplan-Meier curves. d-i, Real-time ratio of non-relapse patients in follow-up patients. The horizontal axis showed follow-up time (month), the left vertical axis showed the number of patients, the right vertical axis showed the real-time ratio of non-relapse patients in follow-up patients. Black dot, the real-time number of patients in following up; Red dot, the real-time number of relapse patients in following up. The blue curve showed the dynamic changes of the real-time ratio of non-relapse patients in follow-up patients.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM13"><media xlink:href="13075_2019_2090_MOESM13_ESM.docx"><caption><p><bold>Additional file 13.</bold> Residuals plot of the IgG4-RD CS prediction model by multiple linear regression. a, Residuals were shown with histogram; b, Residuals appeared completely random showed homoscedasticity.</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>C3</term><def><p id="Par5">Complement 3</p></def></def-item><def-item><term>C4</term><def><p id="Par6">Complement 4</p></def></def-item><def-item><term>CR</term><def><p id="Par7">Complete response</p></def></def-item><def-item><term>CS</term><def><p id="Par8">Composite score</p></def></def-item><def-item><term>CTL</term><def><p id="Par9">Cytotoxic T lymphocytes</p></def></def-item><def-item><term>ESR</term><def><p id="Par10">Erythrocyte sedimentation rate</p></def></def-item><def-item><term>GCs</term><def><p id="Par11">Glucocorticoids</p></def></def-item><def-item><term>Hb</term><def><p id="Par12">Hemoglobin</p></def></def-item><def-item><term>hsCRP</term><def><p id="Par13">Hyper-sensitivity C-reactive protein</p></def></def-item><def-item><term>Ig</term><def><p id="Par14">Immunoglobulin</p></def></def-item><def-item><term>IgG4-RD</term><def><p id="Par15">IgG4-related disease</p></def></def-item><def-item><term>IgG4-RKD</term><def><p id="Par16">IgG4-related kidney disease</p></def></def-item><def-item><term>IMs</term><def><p id="Par17">Immunosuppressive agents</p></def></def-item><def-item><term>NC</term><def><p id="Par18">No change</p></def></def-item><def-item><term>PCA</term><def><p id="Par19">Principal components analysis</p></def></def-item><def-item><term>PCs</term><def><p id="Par20">Principal components</p></def></def-item><def-item><term>Plt</term><def><p id="Par21">Platelet count</p></def></def-item><def-item><term>PR</term><def><p id="Par22">Partial response</p></def></def-item><def-item><term>RI</term><def><p id="Par23">IgG4-RD responder index</p></def></def-item><def-item><term>RTX</term><def><p id="Par24">Rituximab</p></def></def-item><def-item><term>Tfh</term><def><p id="Par25">Follicular helper T cell</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jieqiong Li and Yu Peng contributed equally to this work.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13075-019-2090-9.</p></sec><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JQL and YP designed the study, analyzed the data, and wrote the manuscript. YLZ provided the statistical theory. PPZ, ZL, HL, and LYP collected the data and revised the manuscript. LZ and HDX helped with the imaging diagnosis. YZ and XFZ helped to optimize the research and proofread the paper. WZ and YYF designed the study and wrote the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by CAMS Initiative for Innovative Medicine (2017-12&#x02009;M-3-001), the National Natural Science Foundation of China (81771757 and 81571587), and The National Key Research and Development Program of China [2016YFC0901500].</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par67">The study protocol was approved by the Ethics Committee of Peking Union Medical College Hospital. All the enrolled patients consented to attend this cohort study and signed written consent.</p></notes><notes><title>Consent for publication</title><p id="Par68">We obtained consent for publication from all the individuals whose detailed information was included in this manuscript.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par69">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamisawa</surname><given-names>T</given-names></name><name><surname>Zen</surname><given-names>Y</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name></person-group><article-title>IgG4-related disease</article-title><source>Lancet.</source><year>2015</year><volume>385</volume><issue>9976</issue><fpage>1460</fpage><lpage>1471</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60720-0</pub-id><pub-id pub-id-type="pmid">25481618</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito-Zer&#x000f3;n</surname><given-names>P</given-names></name><name><surname>Bosch</surname><given-names>X</given-names></name><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name></person-group><article-title>IgG4-related disease: advances in the diagnosis and treatment</article-title><source>Best Pract Res Clin Rheumatol</source><year>2016</year><volume>30</volume><issue>2</issue><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2016.07.003</pub-id><pub-id pub-id-type="pmid">27886799</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Mattoo</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Kulikova</surname><given-names>M</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><etal/></person-group><article-title>IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients</article-title><source>Arthritis Rheumatol.</source><year>2015</year><volume>67</volume><issue>9</issue><fpage>2466</fpage><lpage>2475</lpage><pub-id pub-id-type="doi">10.1002/art.39205</pub-id><pub-id pub-id-type="pmid">25988916</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umehara</surname><given-names>H</given-names></name><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Masaki</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Saeki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011</article-title><source>Mod Rheumatol</source><year>2012</year><volume>22</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3109/s10165-011-0571-z</pub-id><pub-id pub-id-type="pmid">22218969</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carruthers</surname><given-names>MN</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Khosroshahi</surname><given-names>A</given-names></name></person-group><article-title>Development of an IgG4-RD responder index</article-title><source>Int J Rheumatol</source><year>2012</year><volume>2012</volume><fpage>259408</fpage><pub-id pub-id-type="doi">10.1155/2012/259408</pub-id><pub-id pub-id-type="pmid">22611406</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>JH</given-names></name><name><surname>Hoffman</surname><given-names>GS</given-names></name><name><surname>Merkel</surname><given-names>PA</given-names></name><name><surname>Min</surname><given-names>YI</given-names></name><name><surname>Uhlfelder</surname><given-names>ML</given-names></name><name><surname>Hellmann</surname><given-names>DB</given-names></name><etal/></person-group><article-title>A disease-specific activity index for Wegener&#x02019;s granulomatosis: modification of the Birmingham Vasculitis activity score. International network for the study of the systemic Vasculitides (INSSYS)</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><issue>4</issue><fpage>912</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200104)44:4&#x0003c;912::AID-ANR148&#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">11318006</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosroshahi</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Crowe</surname><given-names>JL</given-names></name><name><surname>Akamizu</surname><given-names>T</given-names></name><name><surname>Azumi</surname><given-names>A</given-names></name><name><surname>Carruthers</surname><given-names>MN</given-names></name><etal/></person-group><article-title>International consensus guidance statement on the management and treatment of IgG4-related disease</article-title><source>Arthritis Rheumatol</source><year>2015</year><volume>67</volume><issue>7</issue><fpage>1688</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1002/art.39132</pub-id><pub-id pub-id-type="pmid">25809420</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunyun</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Panpan</surname><given-names>Z</given-names></name><name><surname>Hua</surname><given-names>C</given-names></name><name><surname>Di</surname><given-names>W</given-names></name><name><surname>Lidan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>6195</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-06520-5</pub-id><pub-id pub-id-type="pmid">28733656</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunyun</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Panpan</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Linyi</surname><given-names>P</given-names></name><name><surname>Jiaxin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial</article-title><source>Rheumatology (Oxford)</source><year>2019</year><volume>58</volume><issue>1</issue><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/key227</pub-id><pub-id pub-id-type="pmid">30124952</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della-Torre</surname><given-names>E</given-names></name><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Bozzolo</surname><given-names>EP</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Scotti</surname><given-names>R</given-names></name><name><surname>Nicoletti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Methotrexate for maintenance of remission in IgG4-related disease</article-title><source>Rheumatology (Oxford)</source><year>2015</year><volume>54</volume><issue>10</issue><fpage>1934</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kev244</pub-id><pub-id pub-id-type="pmid">26139657</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review</article-title><source>Intern Med J</source><year>2017</year><volume>47</volume><issue>6</issue><fpage>680</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1111/imj.13430</pub-id><pub-id pub-id-type="pmid">28321964</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Mathew</surname><given-names>J</given-names></name><name><surname>Mohan</surname><given-names>H</given-names></name><name><surname>Chowdhury</surname><given-names>SD</given-names></name><name><surname>Kurien</surname><given-names>RT</given-names></name><name><surname>Christopher</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India</article-title><source>Rheumatol Int</source><year>2018</year><volume>38</volume><issue>2</issue><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1007/s00296-017-3730-5</pub-id><pub-id pub-id-type="pmid">28550399</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosroshahi</surname><given-names>A</given-names></name><name><surname>Bloch</surname><given-names>DB</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name></person-group><article-title>Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease</article-title><source>Arthritis Rheum</source><year>2010</year><volume>62</volume><issue>6</issue><fpage>1755</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1002/art.27435</pub-id><pub-id pub-id-type="pmid">20191576</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carruthers</surname><given-names>MN</given-names></name><name><surname>Topazian</surname><given-names>MD</given-names></name><name><surname>Khosroshahi</surname><given-names>A</given-names></name><name><surname>Witzig</surname><given-names>TE</given-names></name><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Hart</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Rituximab for IgG4-related disease: a prospective, open-label trial</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>6</issue><fpage>1171</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206605</pub-id><pub-id pub-id-type="pmid">25667206</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Mattoo</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Kulikova</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><etal/></person-group><article-title>Predictors of disease relapse in IgG4-related disease following rituximab</article-title><source>Rheumatology (Oxford)</source><year>2016</year><volume>55</volume><issue>6</issue><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kev438</pub-id><pub-id pub-id-type="pmid">26888853</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients</article-title><source>Arthritis Res Ther</source><year>2018</year><volume>20</volume><issue>1</issue><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s13075-018-1567-2</pub-id><pub-id pub-id-type="pmid">29636109</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>M</given-names></name><name><surname>Saeki</surname><given-names>T</given-names></name><name><surname>Nakashima</surname><given-names>H</given-names></name><name><surname>Nishi</surname><given-names>S</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Hisano</surname><given-names>S</given-names></name><etal/></person-group><article-title>Proposal for diagnostic criteria for IgG4-related kidney disease</article-title><source>Clin Exp Nephrol</source><year>2011</year><volume>15</volume><issue>5</issue><fpage>615</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1007/s10157-011-0521-2</pub-id><pub-id pub-id-type="pmid">21898030</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Role of complement system in patients with biopsy-proven immunoglobulin G4-related kidney disease</article-title><source>Hum Pathol</source><year>2018</year><volume>81</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2018.07.008</pub-id><pub-id pub-id-type="pmid">30031099</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Fei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients</article-title><source>Rheumatology (Oxford)</source><year>2015</year><volume>54</volume><issue>11</issue><fpage>1982</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kev203</pub-id><pub-id pub-id-type="pmid">26106212</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients</article-title><source>Rheumatology (Oxford)</source><year>2019</year><volume>58</volume><issue>5</issue><fpage>820</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/key397</pub-id><pub-id pub-id-type="pmid">30561747</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Su</surname><given-names>JZ</given-names></name><etal/></person-group><article-title>Internal organ involvement in IgG4-related sialadenitis: a systemic review</article-title><source>Chin J Dent Res</source><year>2015</year><volume>18</volume><issue>2</issue><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">26167546</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>JZ</given-names></name><name><surname>Feng</surname><given-names>RE</given-names></name><name><surname>Shi</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Fei</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Types of organ involvement in patients with immunoglobulin G4-related disease</article-title><source>Chin Med J</source><year>2016</year><volume>129</volume><issue>13</issue><fpage>1525</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.4103/0366-6999.184459</pub-id><pub-id pub-id-type="pmid">27364787</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>GA</given-names></name><name><surname>Bozzolo</surname><given-names>EP</given-names></name><name><surname>Lanzillotta</surname><given-names>M</given-names></name><name><surname>Berti</surname><given-names>A</given-names></name><name><surname>Baldissera</surname><given-names>E</given-names></name><etal/></person-group><article-title>IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients</article-title><source>Scand J Rheumatol</source><year>2016</year><volume>45</volume><issue>2</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.3109/03009742.2015.1055796</pub-id><pub-id pub-id-type="pmid">26398142</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>S</given-names></name><name><surname>Nakayamada</surname><given-names>S</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Sakata</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><etal/></person-group><article-title>Peripheral Immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients</article-title><source>Arthritis Rheumatol.</source><year>2017</year><volume>69</volume><issue>10</issue><fpage>2029</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1002/art.40180</pub-id><pub-id pub-id-type="pmid">28605137</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>JH</given-names></name></person-group><article-title>Hierarchical grouping to optimize an objective function</article-title><source>J Am Stat Assoc</source><year>1963</year><volume>58</volume><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1080/01621459.1963.10500845</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohyama</surname><given-names>K</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Tamai</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Ichinose</surname><given-names>K</given-names></name><name><surname>Kishikawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Immune complexome analysis of antigens in circulating immune complexes isolated from patients with IgG4-related dacryoadenitis and/or sialadenitis</article-title><source>Mod Rheumatol</source><year>2016</year><volume>26</volume><issue>2</issue><fpage>248</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.3109/14397595.2015.1072296</pub-id><pub-id pub-id-type="pmid">26166493</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>ZS</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Perugino</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts</article-title><source>Ann Rheumatic Dis</source><year>2019</year><volume>78</volume><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2018-214603</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawa</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>M</given-names></name><name><surname>Hamano</surname><given-names>H</given-names></name><name><surname>Maruyama</surname><given-names>M</given-names></name><etal/></person-group><article-title>The utility of serum IgG4 concentrations as a biomarker</article-title><source>Int J Rheumatol.</source><year>2012</year><volume>2012</volume><fpage>198314</fpage><pub-id pub-id-type="doi">10.1155/2012/198314</pub-id><pub-id pub-id-type="pmid">22536256</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Saeki</surname><given-names>T</given-names></name><name><surname>Mizushima</surname><given-names>I</given-names></name><name><surname>Matsui</surname><given-names>S</given-names></name><name><surname>Fujisawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases</article-title><source>Arthritis Res Ther.</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>262</fpage><pub-id pub-id-type="doi">10.1186/s13075-017-1467-x</pub-id><pub-id pub-id-type="pmid">29191210</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Risk factors of relapse following glucocorticoid tapering in IgG4-related disease</article-title><source>Clin Exp Rheumatol</source><year>2018</year><volume>36</volume><fpage>186</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">29846165</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>EA</given-names></name><name><surname>Williams</surname><given-names>FK</given-names></name><etal/></person-group><article-title>A mass in the junction of the body and tail of the pancreas with negative IgG4 serology: IgG4-related disease with negative serology</article-title><source>Am J Case Rep</source><year>2015</year><volume>16</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.12659/AJCR.893300</pub-id><pub-id pub-id-type="pmid">26001036</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozzalla Cassione</surname><given-names>E</given-names></name><name><surname>Stone</surname><given-names>JH</given-names></name></person-group><article-title>IgG4-related disease</article-title><source>Curr Opin Rheumatol</source><year>2017</year><volume>29</volume><issue>3</issue><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000383</pub-id><pub-id pub-id-type="pmid">28319486</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Sugihara</surname><given-names>T</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical significance of complement as a biomarker of disease activity in 4 cases of IgG4-related disease with retroperitoneal fibrosis</article-title><source>Clin Exp Rheumatol</source><year>2013</year><volume>31</volume><issue>6</issue><fpage>947</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">24021494</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>M</given-names></name><name><surname>Yoshikawa</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan</article-title><source>Mod Rheumatol</source><year>2018</year><volume>28</volume><issue>5</issue><fpage>845</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1080/14397595.2017.1416891</pub-id><pub-id pub-id-type="pmid">29251026</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culver</surname><given-names>EL</given-names></name><name><surname>Sadler</surname><given-names>R</given-names></name><name><surname>Bateman</surname><given-names>AC</given-names></name><name><surname>Makuch</surname><given-names>M</given-names></name><name><surname>Cargill</surname><given-names>T</given-names></name><name><surname>Ferry</surname><given-names>B</given-names></name><etal/></person-group><article-title>Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease</article-title><source>Clin Gastroenterol Hepatol</source><year>2017</year><volume>15</volume><issue>9</issue><fpage>1444</fpage><lpage>1452.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2017.02.007</pub-id><pub-id pub-id-type="pmid">28223204</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Yasuoka</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Distinct features distinguishing IgG4-related disease from multicentric Castleman&#x02019;s disease</article-title><source>RMD Open</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>e000432</fpage><pub-id pub-id-type="doi">10.1136/rmdopen-2017-000432</pub-id><pub-id pub-id-type="pmid">28959455</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>T</given-names></name></person-group><article-title>IgG4-related lymphadenopathy</article-title><source>Int J Rheumatol.</source><year>2012</year><volume>2012</volume><fpage>572539</fpage><pub-id pub-id-type="doi">10.1155/2012/572539</pub-id><pub-id pub-id-type="pmid">22719769</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasaitis</surname><given-names>L</given-names></name></person-group><article-title>IgG4-related disease: a relatively new concept for clinicians</article-title><source>Eur J Intern Med</source><year>2016</year><volume>27</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2015.09.022</pub-id><pub-id pub-id-type="pmid">26481243</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>D</given-names></name><name><surname>Zwerina</surname><given-names>J</given-names></name><name><surname>Pieringer</surname><given-names>H</given-names></name></person-group><article-title>IgG4-related disease: current challenges and future prospects</article-title><source>Ther Clin Risk Manag</source><year>2016</year><volume>12</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S99985</pub-id><pub-id pub-id-type="pmid">26929632</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Feng</surname><given-names>R</given-names></name><etal/></person-group><article-title>Aberrant expansion and function of follicular helper T cell subsets in IgG4-related disease</article-title><source>Arthritis Rheumatol.</source><year>2018</year><volume>70</volume><issue>11</issue><fpage>1853</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1002/art.40556</pub-id><pub-id pub-id-type="pmid">29781221</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattoo</surname><given-names>H</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Maehara</surname><given-names>T</given-names></name><name><surname>Deshpande</surname><given-names>V</given-names></name><name><surname>Della-Torre</surname><given-names>E</given-names></name><name><surname>Wallace</surname><given-names>ZS</given-names></name><etal/></person-group><article-title>Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease</article-title><source>J Allergy Clin Immunol</source><year>2016</year><volume>138</volume><issue>3</issue><fpage>825</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2015.12.1330</pub-id><pub-id pub-id-type="pmid">26971690</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease</article-title><source>Arthritis Res Ther.</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/s13075-017-1231-2</pub-id><pub-id pub-id-type="pmid">28183334</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heeringa</surname><given-names>JJ</given-names></name><name><surname>Karim</surname><given-names>AF</given-names></name><name><surname>van Laar</surname><given-names>JAM</given-names></name><name><surname>Verdijk</surname><given-names>RM</given-names></name><name><surname>Paridaens</surname><given-names>D</given-names></name><name><surname>van Hagen</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Expansion of blood IgG4+ B, TH2, and regulatory T cells in patients with IgG4-related disease</article-title><source>J Allergy Clin Immunol</source><year>2018</year><volume>141</volume><issue>5</issue><fpage>1831</fpage><lpage>1843.e10</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.07.024</pub-id><pub-id pub-id-type="pmid">28830675</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease</article-title><source>Rheumatology (Oxford)</source><year>2018</year><volume>57</volume><issue>3</issue><fpage>514</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kex455</pub-id><pub-id pub-id-type="pmid">29253269</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>YN</given-names></name><name><surname>Zhan</surname><given-names>YT</given-names></name><etal/></person-group><article-title>IgG4-related disease: association between chronic rhino-sinusitis and systemic symptoms</article-title><source>Eur Arch Otorhinolaryngol</source><year>2018</year><volume>275</volume><issue>8</issue><fpage>2013</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1007/s00405-018-5013-5</pub-id><pub-id pub-id-type="pmid">29948263</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>A</given-names></name><name><surname>Yajima</surname><given-names>R</given-names></name><name><surname>Kakuki</surname><given-names>T</given-names></name><name><surname>Jitsukawa</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical evaluation of sinonasal lesions in patients with immunoglobulin G4-related disease</article-title><source>Ann Otol Rhinol Laryngol</source><year>2015</year><volume>124</volume><issue>12</issue><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1177/0003489415593557</pub-id><pub-id pub-id-type="pmid">26148490</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgs</surname><given-names>BW</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Sebastian</surname><given-names>Y</given-names></name><name><surname>Morehouse</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><etal/></person-group><article-title>High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>17567</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17602-9</pub-id><pub-id pub-id-type="pmid">29242501</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saraya</surname><given-names>T</given-names></name><name><surname>Ohkuma</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><name><surname>Miyaoka</surname><given-names>C</given-names></name><name><surname>Wada</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical characterization of 52 patients with immunoglobulin G4-related disease in a single tertiary center in Japan: special reference to lung disease in thoracic high-resolution computed tomography</article-title><source>Respir Med</source><year>2017</year><volume>132</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.09.006</pub-id><pub-id pub-id-type="pmid">29229107</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyama</surname><given-names>K</given-names></name><name><surname>Yoshifuji</surname><given-names>H</given-names></name><name><surname>Kandou</surname><given-names>T</given-names></name><name><surname>Hosono</surname><given-names>Y</given-names></name><name><surname>Kitagori</surname><given-names>K</given-names></name><name><surname>Nakashima</surname><given-names>R</given-names></name><etal/></person-group><article-title>Screening for IgG4-type anti-nuclear antibodies in IgG4-related disease</article-title><source>BMC Musculoskelet Disord</source><year>2015</year><volume>16</volume><fpage>129</fpage><pub-id pub-id-type="doi">10.1186/s12891-015-0584-4</pub-id><pub-id pub-id-type="pmid">26018403</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragoulis</surname><given-names>GE</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group><article-title>IgG4 syndrome: old disease, new perspective</article-title><source>J Rheumatol</source><year>2010</year><volume>37</volume><issue>7</issue><fpage>1369</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.3899/jrheum.100383</pub-id><pub-id pub-id-type="pmid">20595288</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fragoulis</surname><given-names>GE</given-names></name><name><surname>Zampeli</surname><given-names>E</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group><article-title>IgG4-related sialadenitis and Sj&#x000f6;gren's syndrome</article-title><source>Oral Dis</source><year>2017</year><volume>23</volume><issue>2</issue><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1111/odi.12526</pub-id><pub-id pub-id-type="pmid">27318181</pub-id></element-citation></ref></ref-list></back></article>